Brief: Abionyx Pharma Announces Positive Signals In ATUN For Ultra-Rare Kidney Disease
Nov 25 (Reuters) - ABIONYX PHARMA SA ABNX.PA :
* ANNOUNCES OBSERVATION OF POSITIVE THERAPEUTIC SIGNALS IN
TEMPORARY AUTHORIZATIONS FOR USE (ATUN) IN FRANCE AND ITALY FOR
AN ULTRA-RARE KIDNEY DISEASE
* EXCELLENT TOLERABILITY OF CER-001
* ABIONYX IS AWAITING DATA FROM OTHER ONGOING PRECLINICAL
STUDIES
Source text for Eikon: ID:nNDL37D39M
Further company coverage: ABNX.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Abionyx Pharma SA
See all newsBrief: ABIONYX Pharma And OLON Enter Into Strategic Manufacturing Partnership
France's ABIONYX Pharma H1 net loss widens as financial expenses rise
Brief: ABIONYX Pharma H1 EBIT EUR -2.27 Million
Abionyx jumps as Stifel starts coverage with 'buy'
Cardiovascular drug developer ABIONYX Pharma's H1 revenue falls